in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance. .
yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital.
. biohaven: "rimegepant pivotal phase 3 trial results -- conference call."
.
.
connect with kpcc
.
Popular Stores